Selected high-signal discussions on tissue oxygenation, microcirculation, oxygen delivery, transfusion resilience and the scientific history of Biopure, Hemopure, Oxyglobin and oxygen therapeutics.
A discussion of why endothelial dysfunction, microcirculatory impairment, edema, microthrombosis and altered nitric oxide biology can limit oxygen delivery even when conventional blood-level measurements appear adequate. The discussion was also picked up by Hemostasis Today.
Open publication ↗A reflection on the scientific relationship of Bing Lou Wong and Carl Rausch, from their early work at Tufts University through Biopure, Hemopure and Oxyglobin, and into the continuing development of oxygen therapeutics. The story connects technology with the people, persistence and institutional memory behind it.
Open recent LinkedIn activity ↗Franck Zal (HEMARINA) shared the BHOC Historical Evolution discussion and added his own perspective on evolution, globin biology, naturally extracellular hemoglobin M101 and therapeutic oxygen delivery.
Open Franck Zal's discussion ↗David N. Judelson played a major strategic role during Biopure's development years. The post looks at the people, capital and regulatory environment behind one of the earliest commercial oxygen-carrier platforms.
Open publication ↗A look at U.S. military collaboration around Hemopure and its relevance to trauma, battlefield medicine and donor-independent oxygen-carrying support in difficult environments.
Open publication ↗Examines repeated blood-shortage warnings across multiple national blood systems and the strategic need to think beyond donor recruitment alone toward functional oxygen-delivery resilience.
Open publication ↗Prehospital transfusion is moving closer to the point of injury. The post examines where BHOC and Precision Oxygenation Therapeutics may complement donor blood when availability, logistics, storage or time constrain field resuscitation.
Open publication ↗A BHOC discussion of the 2015 PNAS βCys93 study: normal hemoglobin concentration and oxygen-carrying capacity did not prevent impaired hypoxic vasodilation and reduced tissue oxygenation when a key hemoglobin NO-signaling site was disrupted. The evidence reinforces that oxygen content, vascular regulation and microcirculatory flow must be considered together.
Open indexed summary →The BHOC Evidence Platform remains the structured scientific source base. LinkedIn publications and selected external expert perspectives connect evidence, historical context and strategic questions with public professional discussion.